Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

Company Overview

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a clinical-stage biopharmaceutical company headquartered in New York City that focuses on the development of novel small-molecule therapies for central nervous system (CNS) disorders. Since its founding in 2002, the company has pursued an intracellular signaling approach to address conditions such as schizophrenia, bipolar depression and neuropsychiatric manifestations of Parkinson’s disease. Its research platform is built on the modulation of key neurotransmitter receptors and intracellular pathways, distinguishing its pipeline from traditional receptor-targeted drug candidates.

The company’s flagship product, lumateperone (marketed as CAPLYTA®), is approved in the United States for the treatment of schizophrenia in adults and for bipolar depression in adults. Lumateperone’s mechanism of action involves simultaneous modulation of serotonin, dopamine and glutamate signaling, offering a differentiated side-effect profile compared to existing antipsychotics. In addition to its approved indications, Intra-Cellular Therapies is pursuing regulatory filings in multiple territories and is exploring additional psychiatric and neurological indications for lumateperone.

Beyond CAPLYTA®, ITCI’s pipeline includes early-stage programs such as ITI-333, which targets non-motor symptoms of Parkinson’s disease and REM sleep behavior disorder, and ITI-214, a phosphodiesterase-1 inhibitor in development for cognitive impairment associated with schizophrenia. The company conducts its clinical trials primarily in North America and Europe, leveraging strategic partnerships and academic collaborations to support patient enrollment and translational research efforts.

Under the guidance of a leadership team with deep expertise in neuropsychopharmacology, Intra-Cellular Therapies has built its organizational capabilities around clinical development, regulatory strategy and commercialization readiness. The company’s co-founders and executive management maintain active engagement with scientific advisory boards and professional societies, ensuring that its research advances reflect evolving standards in CNS drug development.

Key Stats

• Today's Range: $131.87 to $131.87
• 50-Day Range: $131.87 to $131.87
• 52-Week Range: $67.68 to $131.98
• Volume: N/A
• Average Volume: 1.52 million shs
• Market Capitalization: $14.05 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $109.70
• Consensus Rating: Hold

Intra-Cellular Therapies Stock Analysis - MarketRank™

Intra-Cellular Therapies scored higher than 18% of companies evaluated by MarketBeat, and ranked 880th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 10 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Intra-Cellular Therapies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.19 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intra-Cellular Therapies has a P/B Ratio of 21.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ITCI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intra-Cellular Therapies does not currently pay a dividend.

Dividend Growth

Intra-Cellular Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.23

Short Interest

There is no current short interest data available for ITCI.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.60% of the stock of Intra-Cellular Therapies is held by insiders.

Percentage Held by Institutions

92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ITCI Stock Analysis - Frequently Asked Questions

How have ITCI shares performed this year?

Intra-Cellular Therapies' stock was trading at $83.52 at the start of the year. Since then, ITCI shares have increased by 57.9% and is now trading at $131.87.
View the best growth stocks for 2025 here.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings results on Friday, February, 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.08. The biopharmaceutical company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 9.93% and a negative net margin of 14.07%.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 2/21/2025
• Today: 7/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ITCI
• CIK: 1567514
• Web: www.intracellulartherapies.com
• Phone: (464) 440-9333
• Fax: 646-440-9334
• Employees: 560
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $109.70
• High Stock Price Target: $132.00
• Low Stock Price Target: $74.00
• Potential Upside/Downside: -16.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$139.67 million
• Net Margins: -14.07%
• Pretax Margin: -13.87%
• Return on Equity: -9.93%
• Return on Assets: -8.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.66
• Quick Ratio: 7.51

Sales & Book Value

• Annual Sales: $680.50 million
• Price / Sales: 20.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.15 per share
• Price / Book: 21.44

Miscellaneous

• Outstanding Shares: 106,522,000
• Free Float: 103,563,000
• Market Cap: $14.05 billion
• Optionable: Optionable
• Beta: 0.69